Cardiotoxicity of immune checkpoint inhibitors: An updated review,Biotechnology and Applied Biochemistry

当前位置： X-MOL 学术 › Biotechnol. Appl. Bioc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cardiotoxicity of immune checkpoint inhibitors: An updated review
Biotechnology and Applied Biochemistry ( IF 3.2 ) Pub Date : 2020-12-02 , DOI: 10.1002/bab.2081
Soheil Behravesh ₁ , Navid Shomali ₂ , Gholamreza Rezaei Danbaran ₁ , Saeed Aslani ₃ , Maryam Hemmatzadeh ₂ , Ramin Hosseinzadeh ₃ , Arezoo Gowhari-Shabgah ₄ , Hamed Mohammadi _{5,

6}

Affiliation

The immune checkpoint molecules are involved in the regulation of T cells in order to prevent them from attacking to sell tissues and play a role in the immune response homeostasis. Application of the immune checkpoint inhibitors (ICIs) has provided a promising therapeutic approach in pathologies where the immune system is suppressed. The extended utilization of ICIs in several cancers has caused immune-related side effects in the cardiovascular system like cardiomyopathy and myocarditis. Cardiac toxicity, one of the main side effects of the ICIs-based therapeutic approach, has less been concerned; however, during the last years, many cases of fatal heart failure and myocarditis have been reported in patients treated with ICIs. In this review article, we attempted to discuss the cardiac adverse effects of inhibiting different immune checkpoint molecules.

中文翻译：

免疫检查点抑制剂的心脏毒性：最新综述

免疫检查点分子参与调节 T 细胞，以防止它们攻击出售组织并在免疫反应稳态中发挥作用。免疫检查点抑制剂 (ICI) 的应用为免疫系统受到抑制的病理提供了一种有前途的治疗方法。在几种癌症中广泛使用 ICI 已在心血管系统中引起与免疫相关的副作用，如心肌病和心肌炎。心脏毒性是基于 ICI 的治疗方法的主要副作用之一，很少受到关注；然而，在过去几年中，在接受 ICI 治疗的患者中报告了许多致命的心力衰竭和心肌炎病例。在这篇评论文章中，

更新日期：2020-12-02

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11